| Synonym |
| Thai / English name |
Part Used : รากActivity : DRUG INTERACTIONSolvent/Active Compound : ginsenoside Rg3Type of experiment : in vivoType of animal : mouseType of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : Oral administrationDose/Conc.(herb) : CT-26 cell-inoculated group treated with105 mg/kg Rg3 plus 5 mg/kg cisplatin, once daily.Duration : 15 daysType of interaction : PharmacodynamicsInteraction with drug : Cisplatin*/CDDPDose/Conc.(drug) : -Result : PositiveRemark : Result: Rg3 treatment prevented these cisplatin-mediated increases in serum NO and tissue MDA levels and decreases in tissue GSH levels.Note : CT-26 mouse colon cancer cells (2x10^6 cells) suspended in 0.1 ml phosphate buffered saline (PBS) were subcutaneously injected into the right flanks of the mice. Twenty-four hours later, the mice were given Rg3 (5 or 10 mg/kg body weight (BW)) in PBS via oral gavage. Two hours later, cisplatin (2 or 5 mg/kg BW) dissolved in PBS was intraperitoneally injected. Rg3 and/or cisplatin were administered once per day for 15 days.
Part Used : รากActivity : DRUG INTERACTIONSolvent/Active Compound : ginsenoside Rg3Type of experiment : in vivoType of animal : mouseType of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : Oral administrationDose/Conc.(herb) : CT-26 cell-inoculated group treated with 5 mg/kg Rg3 plus 5 mg/kg cisplatin, once daily.Duration : 15 daysType of interaction : PharmacodynamicsInteraction with drug : Cisplatin*/CDDPDose/Conc.(drug) : -Result : PositiveRemark : Result: The administration of Rg3 blocked the cisplatin-induced reduction in the activities of the antioxidant enzymes glutathione peroxidase (GSH-Px), superoxide dismutase (SOD) and catalase.Note : CT-26 mouse colon cancer cells (2x10^6 cells) suspended in 0.1 ml phosphate buffered saline (PBS) were subcutaneously injected into the right flanks of the mice. Twenty-four hours later, the mice were given Rg3 (5 or 10 mg/kg body weight (BW)) in PBS via oral gavage. Two hours later, cisplatin (2 or 5 mg/kg BW) dissolved in PBS was intraperitoneally injected. Rg3 and/or cisplatin were administered once per day for 15 days.
Part Used : รากActivity : DRUG INTERACTIONSolvent/Active Compound : ginsenoside Rg3Type of experiment : in vivoType of animal : mouseType of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : Oral administrationDose/Conc.(herb) : CT-26 cell-inoculated group treated with 10 mg/kg Rg3 plus 5 mg/kg cisplatin, once daily.Duration : 15 daysType of interaction : PharmacodynamicsInteraction with drug : Cisplatin*/CDDPDose/Conc.(drug) : -Result : PositiveRemark : Result: The administration of Rg3 blocked the cisplatin-induced reduction in the activities of the antioxidant enzymes glutathione peroxidase (GSH-Px), superoxide dismutase (SOD) and catalase.Note : CT-26 mouse colon cancer cells (2x10^6 cells) suspended in 0.1 ml phosphate buffered saline (PBS) were subcutaneously injected into the right flanks of the mice. Twenty-four hours later, the mice were given Rg3 (5 or 10 mg/kg body weight (BW)) in PBS via oral gavage. Two hours later, cisplatin (2 or 5 mg/kg BW) dissolved in PBS was intraperitoneally injected. Rg3 and/or cisplatin were administered once per day for 15 days.
Part Used : รากActivity : DRUG INTERACTIONSolvent/Active Compound : ginsenoside Rg3Type of experiment : in vivoType of animal : mouseType of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : Oral administrationDose/Conc.(herb) : CT-26 cell-inoculated group treated with 5 mg/kg Rg3 plus 5 mg/kg cisplatin, once daily.Duration : 15 daysType of interaction : PharmacodynamicsInteraction with drug : Cisplatin*/CDDPDose/Conc.(drug) : -Result : PositiveRemark : Result: The 3-nitrotyrosine (3-NT) level was increased in response to cisplatin treatment in kidney and liver tissues, but the oral administration of Rg3 effectively prevented these cisplatin-induced histopathological changes and 3-NT production. These results indicate that Rg3 administration suppresses nephrotoxicity, hepatotoxicity, and oxidative stress in the kidney and liver tissues of cisplatin treated mice.Note : CT-26 mouse colon cancer cells (2x10^6 cells) suspended in 0.1 ml phosphate buffered saline (PBS) were subcutaneously injected into the right flanks of the mice. Twenty-four hours later, the mice were given Rg3 (5 or 10 mg/kg body weight (BW)) in PBS via oral gavage. Two hours later, cisplatin (2 or 5 mg/kg BW) dissolved in PBS was intraperitoneally injected. Rg3 and/or cisplatin were administered once per day for 15 days.
Part Used : รากActivity : DRUG INTERACTIONSolvent/Active Compound : ginsenoside Rg3Type of experiment : in vivoType of animal : mouseType of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : 50 micrograms cisplatin + 10 micrograms Rg3Duration : -Type of interaction : PharmacodynamicsInteraction with drug : Cisplatin*/CDDPDose/Conc.(drug) : -Result : PositiveRemark : Result: Tretment with Rg3 or the antioxidant NAC 2 h prior to cisplatin treatment recovered the viability of cisplatin-treated normal kidney (LLC-RK1) and liver (NCTC1469) cells by inhibiting the reduction in DNA synthesis and the increase in apoptotic cell death. Rg3 at noncytotoxic doses may protect normal cells against cisplatin-induced cytotoxicity but does not reduce cisplatin-induced cytotoxicity in cancer cells.Note : CT-26 mouse colon cancer cells (2x10^6 cells) suspended in 0.1 ml phosphate buffered saline (PBS) were subcutaneously injected into the right flanks of the mice. Twenty-four hours later, the mice were given Rg3 (5 or 10 mg/kg body weight (BW)) in PBS via oral gavage. Two hours later, cisplatin (2 or 5 mg/kg BW) dissolved in PBS was intraperitoneally injected. Rg3 and/or cisplatin were administered once per day for 15 days.
Part Used : รากActivity : DRUG INTERACTIONSolvent/Active Compound : ginsenoside Rg3Type of experiment : in vivoType of animal : mouseType of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : 50 micrograms cisplatin + 20 micrograms Rg3Duration : -Type of interaction : PharmacodynamicsInteraction with drug : Cisplatin*/CDDPDose/Conc.(drug) : -Result : PositiveRemark : Result: Tretment with Rg3 or the antioxidant NAC 2 h prior to cisplatin treatment recovered the viability of cisplatin-treated normal kidney (LLC-RK1) and liver (NCTC1469) cells by inhibiting the reduction in DNA synthesis and the increase in apoptotic cell death. Rg3 at noncytotoxic doses may protect normal cells against cisplatin-induced cytotoxicity but does not reduce cisplatin-induced cytotoxicity in cancer cells.Note : CT-26 mouse colon cancer cells (2x10^6 cells) suspended in 0.1 ml phosphate buffered saline (PBS) were subcutaneously injected into the right flanks of the mice. Twenty-four hours later, the mice were given Rg3 (5 or 10 mg/kg body weight (BW)) in PBS via oral gavage. Two hours later, cisplatin (2 or 5 mg/kg BW) dissolved in PBS was intraperitoneally injected. Rg3 and/or cisplatin were administered once per day for 15 days.
Part Used : รากActivity : DRUG INTERACTIONSolvent/Active Compound : ginsenoside Rg3Type of experiment : in vivoType of animal : mouseType of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : 500 micrograms cisplatin + 25 micrograms Rg3Duration : -Type of interaction : PharmacodynamicsInteraction with drug : Cisplatin*/CDDPDose/Conc.(drug) : -Result : PositiveRemark : Result: Neither Rg3 nor NAC restored the viability of cisplatin-treated CT-26 cancer cells. Rg3 in combination with cisplatin resulted in increased inhibition of DNA synthesis in proliferating cells and stimulated more apoptotic cell death compared with CT-26 cells treated with cisplatin alone. Therefore, Rg3 at noncytotoxic doses may protect normal cells against cisplatin-induced cytotoxicity but does not reduce cisplatin-induced cytotoxicity in cancer cells.Note : CT-26 mouse colon cancer cells (2x10^6 cells) suspended in 0.1 ml phosphate buffered saline (PBS) were subcutaneously injected into the right flanks of the mice. Twenty-four hours later, the mice were given Rg3 (5 or 10 mg/kg body weight (BW)) in PBS via oral gavage. Two hours later, cisplatin (2 or 5 mg/kg BW) dissolved in PBS was intraperitoneally injected. Rg3 and/or cisplatin were administered once per day for 15 days.
Part Used : รากActivity : DRUG INTERACTIONSolvent/Active Compound : ginsenoside Rg3Type of experiment : in vivoType of animal : mouseType of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : 500 micrograms cisplatin + 50 micrograms Rg3Duration : -Type of interaction : PharmacodynamicsInteraction with drug : Cisplatin*/CDDPDose/Conc.(drug) : -Result : PositiveRemark : Result: Neither Rg3 nor NAC restored the viability of cisplatin-treated CT-26 cancer cells. Rg3 in combination with cisplatin resulted in increased inhibition of DNA synthesis in proliferating cells and stimulated more apoptotic cell death compared with CT-26 cells treated with cisplatin alone. Therefore, Rg3 at noncytotoxic doses may protect normal cells against cisplatin-induced cytotoxicity but does not reduce cisplatin-induced cytotoxicity in cancer cells.Note : CT-26 mouse colon cancer cells (2x10^6 cells) suspended in 0.1 ml phosphate buffered saline (PBS) were subcutaneously injected into the right flanks of the mice. Twenty-four hours later, the mice were given Rg3 (5 or 10 mg/kg body weight (BW)) in PBS via oral gavage. Two hours later, cisplatin (2 or 5 mg/kg BW) dissolved in PBS was intraperitoneally injected. Rg3 and/or cisplatin were administered once per day for 15 days.
Part Used : รากActivity : DRUG INTERACTIONSolvent/Active Compound : ginsenoside Rg3Type of experiment : in vivoType of animal : mouseType of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : Oral administrationDose/Conc.(herb) : CT-26 cell-inoculated group treated with 5 mg/kg Rg3 plus 5 mg/kg cisplatin, once daily.Duration : 15 daysType of interaction : PharmacodynamicsInteraction with drug : Cisplatin*/CDDPDose/Conc.(drug) : -Result : PositiveRemark : Result: HO-1 and NQO-1 levels were noticeably induced in all tissues in response to cisplatin treatment. However, cisplatin-induced HO-1 and NQO-1 expression was inhibited by co-administration of Rg3.Note : CT-26 mouse colon cancer cells (2x10^6 cells) suspended in 0.1 ml phosphate buffered saline (PBS) were subcutaneously injected into the right flanks of the mice. Twenty-four hours later, the mice were given Rg3 (5 or 10 mg/kg body weight (BW)) in PBS via oral gavage. Two hours later, cisplatin (2 or 5 mg/kg BW) dissolved in PBS was intraperitoneally injected. Rg3 and/or cisplatin were administered once per day for 15 days.
Part Used : รากActivity : DRUG INTERACTIONSolvent/Active Compound : ginsenoside Rg3Type of experiment : in vivoType of animal : mouseType of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : Oral administrationDose/Conc.(herb) : CT-26 cell-inoculated group treated with 10 mg/kg Rg3 plus 5 mg/kg cisplatin, once daily.Duration : 15 daysType of interaction : PharmacodynamicsInteraction with drug : Cisplatin*/CDDPDose/Conc.(drug) : -Result : PositiveRemark : Result: HO-1 and NQO-1 levels were noticeably induced in all tissues in response to cisplatin treatment. However, cisplatin-induced HO-1 and NQO-1 expression was inhibited by co-administration of Rg3.Note : CT-26 mouse colon cancer cells (2x10^6 cells) suspended in 0.1 ml phosphate buffered saline (PBS) were subcutaneously injected into the right flanks of the mice. Twenty-four hours later, the mice were given Rg3 (5 or 10 mg/kg body weight (BW)) in PBS via oral gavage. Two hours later, cisplatin (2 or 5 mg/kg BW) dissolved in PBS was intraperitoneally injected. Rg3 and/or cisplatin were administered once per day for 15 days.
